SG11201912163WA - Compositions and methods for cancer therapy with dengue virus and dendritic cells - Google Patents

Compositions and methods for cancer therapy with dengue virus and dendritic cells

Info

Publication number
SG11201912163WA
SG11201912163WA SG11201912163WA SG11201912163WA SG11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA SG 11201912163W A SG11201912163W A SG 11201912163WA
Authority
SG
Singapore
Prior art keywords
compositions
methods
dendritic cells
cancer therapy
dengue virus
Prior art date
Application number
SG11201912163WA
Other languages
English (en)
Inventor
Bruce W Lyday
Tony Chen
Original Assignee
Primevax Immuno Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primevax Immuno Oncology Inc filed Critical Primevax Immuno Oncology Inc
Publication of SG11201912163WA publication Critical patent/SG11201912163WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201912163WA 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells SG11201912163WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520345P 2017-06-15 2017-06-15
PCT/US2018/037616 WO2018232166A1 (en) 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells

Publications (1)

Publication Number Publication Date
SG11201912163WA true SG11201912163WA (en) 2020-01-30

Family

ID=64660234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912163WA SG11201912163WA (en) 2017-06-15 2018-06-14 Compositions and methods for cancer therapy with dengue virus and dendritic cells

Country Status (11)

Country Link
US (1) US20200121745A1 (https=)
EP (1) EP3638303A4 (https=)
JP (1) JP2020527540A (https=)
KR (1) KR20200023375A (https=)
CN (1) CN110996997A (https=)
AU (1) AU2018285525A1 (https=)
EA (1) EA201992863A1 (https=)
IL (1) IL271442A (https=)
MX (1) MX2019015194A (https=)
SG (1) SG11201912163WA (https=)
WO (1) WO2018232166A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107921063A (zh) 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
JP2020500847A (ja) 2016-11-16 2020-01-16 プライムヴァックス イミュノ−オンコロジー，インク． 癌の処置のための併用免疫療法
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
CN115666593B (zh) * 2020-05-21 2025-11-25 国立大学法人大阪大学 上皮癌治疗药
WO2022061811A1 (zh) * 2020-09-27 2022-03-31 深圳华大生命科学研究院 药物组合物及其制备方法和应用
CN116333969A (zh) * 2023-02-01 2023-06-27 宁波荣安生物药业有限公司 一种狂犬病毒用Vero细胞培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1056834A2 (en) * 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US6524587B1 (en) * 1998-05-05 2003-02-25 Bruce W. Lyday Hyperthermia and immunotherapy for leukemias lymphomas, and solid tumors
JP2002540168A (ja) * 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 多価デングウイルスワクチン
CN107921063A (zh) * 2015-07-02 2018-04-17 普莱瓦克斯免疫肿瘤学公司 用于采用登革病毒与树突细胞的联合疗法的组合物及方法
CN108291205A (zh) * 2015-09-26 2018-07-17 普莱瓦克斯免疫肿瘤学公司 用于产生树突细胞的组合物和方法
EP3565567A4 (en) * 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS

Also Published As

Publication number Publication date
CN110996997A (zh) 2020-04-10
KR20200023375A (ko) 2020-03-04
EP3638303A1 (en) 2020-04-22
AU2018285525A1 (en) 2020-01-30
IL271442A (en) 2020-01-30
US20200121745A1 (en) 2020-04-23
EP3638303A4 (en) 2021-03-10
EA201992863A1 (ru) 2020-05-06
WO2018232166A1 (en) 2018-12-20
MX2019015194A (es) 2020-08-03
JP2020527540A (ja) 2020-09-10

Similar Documents

Publication Publication Date Title
AU2022231657A1 (en) Compositions and Methods for Treating Cancer
IL304820A (en) Preparations and methods for the treatment of cancer
SG11201912163WA (en) Compositions and methods for cancer therapy with dengue virus and dendritic cells
EP3936154B8 (en) Compositions and methods for viral cancer neoepitopes
GB201609438D0 (en) Compositions and methods for cell targeted HPV treatment
IL253658A0 (en) Combined treatment with coagulation factors and multispecific antibodies
IL265786A (en) Materials and methods for increasing radiotherapy against cancer
IL251951A0 (en) Methods and compositions for natural killer cells
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
ZA202100234B (en) Methods and compositions using recombinant dendritic cells for cancer therapy
IL282447A (en) Methods and preparations for healing eye cell
IL256523A (en) Compositions and methods for treating cancer
EP3096787A4 (en) Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
HUE047540T2 (hu) Javított allogén dendritikus sejtek rák kezelésében történõ alkalmazásra
IL246607A0 (en) Improved cellular preparations and methods for cancer treatment
EP3215163A4 (en) Beta-glucan methods and compositions that affect the tumor microenvironment
IL263218A (en) Compounds and methods for microbiotic therapy
EP3145516A4 (en) Methods and compositions for treating malignancies with dendritic cells
IL255638A (en) Compositions and methods for treating cancer
IL271022A (en) Compositions and methods for providing cell replacement therapy
EP3166637A4 (en) Compositions and methods for treating dengue virus infection
EP3169333A4 (en) Methods and compositions for enhancing cancer therapy
IL268268B (en) Methods and compounds for the evaluation of cancerous tumors
IL313283A (en) Methods related to activated stem cell preparations and immunotherapeutic cures for patients with advanced cancers
SG11201702260RA (en) Anti-cancer agent and cancer cell killing method